Black Diamond Therapeutics

Black Diamond Therapeutics

  • Founded: 2014
  • Location: Stony Brook, NY
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Multiple cancers
  • Drug types: ONC
  • Lead product: BDTX-1535
  • Product link:
  • Funding: $75M stock Jun 2023; $231M IPO Jan 2020; $85M C Dec 2019; $85M B Jan 2019; $20M A 2017
  • Investors: Versant Ventures, Boxer Capital, Wellington Management Company, BVF Partners L.P., Deerfield Management,Janus Henderson Investors, Casdin Capital, Logos Capital, New Enterprise Associates, RA Capital Management, Nextech Invest, Invus, Perceptive Advisors, City Hill Ventures, Roche Venture Fund

job board

Short description:

Targeting allosteric mutant oncogenes

Drug notes:

BDTX-4933 Clin0 solid tumors, CNS tumors; 2 undisclosed programs RD solid tumors

Long description:

Black Diamond Therapeutics is developing small molecule therapies to meet the unmet need for precision oncology. Cancer is a genetic disease of which many are caused by mutations in oncogenes. Using their proprietary Mutation-Allostery-Pharmacology (MAP) drug discovery engine, Black Diamond is analyzing population-level genetic sequencing data to identify oncogenic mutations that promote cancer and aggregate the mutations into families. After creating mutation families, Black Diamond can develop a single spectrum-selective therapy that targets a specific family of mutations. Using their MAP discovery engine, Black Diamond is developing a pipeline of orally available, potent and selective drug candidates including their lead candidate, BDTX-1535, a brain-penetrant inhibitor of EGFR mutations.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy